
    
      This is a Phase 3, multi-center, open-label study to evaluate the safety and tolerability of
      ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic
      nOH. The study consists of 3 periods: (i) 26-week treatment, (ii) 156-week treatment
      extension, and (iii) 2-week follow-up.
    
  